These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30975663)

  • 1. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
    Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
    Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
    Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype.
    Madsen RR; Erickson EC; Rueda OM; Robin X; Caldas C; Toker A; Semple RK; Vanhaesebroeck B
    PLoS Genet; 2021 Nov; 17(11):e1009876. PubMed ID: 34762647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
    Guan R; Kang Z; Li L; Yan X; Gao T
    PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
    Zheng S; He S; Liang Y; Tan Y; Liu Q; Liu T; Lu X
    Mol Biomed; 2024 Apr; 5(1):13. PubMed ID: 38616230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
    Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
    Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
    Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.
    Sirico M; Jacobs F; Molinelli C; Nader-Marta G; Debien V; Dewhurst HF; Palleschi M; Merloni F; Gianni C; De Giorgi U; de Azambuja E
    Crit Rev Oncol Hematol; 2024 Aug; 200():104404. PubMed ID: 38815877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
    Gris-Oliver A; Ibrahim YH; Rivas MA; García-García C; Sánchez-Guixé M; Ruiz-Pace F; Viaplana C; Pérez-García JM; Llombart-Cussac A; Grueso J; Parés M; Guzmán M; Rodríguez O; Anton P; Cozar P; Calvo MT; Bruna A; Arribas J; Caldas C; Dienstmann R; Nuciforo P; Oliveira M; Cortés J; Serra V
    Br J Cancer; 2021 Apr; 124(9):1581-1591. PubMed ID: 33723394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
    Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.
    Ocana A; Vera-Badillo F; Al-Mubarak M; Templeton AJ; Corrales-Sanchez V; Diez-Gonzalez L; Cuenca-Lopez MD; Seruga B; Pandiella A; Amir E
    PLoS One; 2014; 9(4):e95219. PubMed ID: 24777052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PI3K/AKT/mTOR network for treatment of leukemia.
    Bertacchini J; Heidari N; Mediani L; Capitani S; Shahjahani M; Ahmadzadeh A; Saki N
    Cell Mol Life Sci; 2015 Jun; 72(12):2337-47. PubMed ID: 25712020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
    Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
    Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
    J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.